Tumours exist in a hypoxic microenvironment and must limit excessive oxygen consumption. Hypoxia-inducible factor (HIF) controls mitochondrial oxygen consumption, but how/if tumours regulate non-mitochondrial oxygen consumption (NMOC) is unknown. Protein-tyrosine phosphatase-1B (PTP1B) is required for Her2/Neu-driven breast cancer (BC) in mice, although the underlying mechanism and human relevance remain unclear. We found that PTP1B-deficient HER2 + xenografts have increased hypoxia, necrosis and impaired growth. In vitro, PTP1B deficiency sensitizes HER2 + BC lines to hypoxia by increasing NMOC by α-KG-dependent dioxygenases (α-KGDDs). The moyamoya disease gene product RNF213, an E3 ligase, is negatively regulated by PTP1B in HER2 + BC cells. RNF213 knockdown reverses the effects of PTP1B deficiency on α-KGDDs, NMOC and hypoxia-induced death of HER2 + BC cells, and partially restores tumorigenicity. We conclude that PTP1B acts via RNF213 to suppress α-KGDD activity and NMOC. This PTP1B/RNF213/α-KGDD pathway is critical for survival of HER2 + BC, and possibly other malignancies, in the hypoxic tumour microenvironment.
Many, if not most, solid tumours contain significant areas of hypoxia or anoxia 1 . Cells activate three major adaptive pathways in response to oxygen deficit, which together function to limit O 2 consumption and maintain energy balance/metabolism 2 . In response to even mild hypoxia, the transcription factor HIF1α becomes stabilized. HIF1α directs the expression of multiple genes, which promote neo-vascularization, suppress protein synthesis, increase glycolysis and decrease mitochondrial O 2 consumption. More severe hypoxia activates AMPK, which suppresses mTOR and limits excess energy consumption from the synthesis of protein, lipid and other macromolecules 3, 4 . Severe hypoxia also causes endoplasmic (ER) stress and activates the unfolded protein response (UPR). The UPR activates three distinct ER sensors for unfolded proteins, PERK, IRE1 and ATF6 5 . Together, they impede translation and induce the expression of genes for protein refolding and ER redox balance. Although mitochondria are responsible for the vast majority of cellular oxygen consumption, a number of biological processes, including, but not limited to, protein folding, lipid and collagen synthesis, and DNA and histone demethylation, involve reactions that utilize oxygen directly. Whether (and how) non-mitochondrial oxygen consumption (NMOC) is regulated during oxygen deprivation is unknown.
Mammals have a large family of genes (>60) encoding α-KG (α-ketoglutarate)-dependent dioxygenases (α-KGDDs), which use α-KG and O 2 as co-substrates to catalyse hydroxylation and demethylation reactions [6] [7] [8] [9] . These enzymes require Fe +2 and typically, ascorbate (vitamin C), which functions to maintain the oxidation state of the Fe residue [7] [8] [9] [10] . Examples of α-KGDDs include the HIF prolyl hydroxylases (PHD1-3), which direct HIF ubiquitylation and are critical for its regulation by O 2 , the FIH asparaginyl hydroxylase, which regulates HIF association with P300, TET family DNA demethylases, the Jumanji histone demethylases, the collagen hydroxylases and a key enzyme in carnitine metabolism, γ-butyrobetaine hydroxylase (BBOX).
The protein-tyrosine phosphatase PTP1B, encoded by PTPN1, is best known as an essential regulator of insulin and leptin receptor signalling; accordingly, Ptpn1 −/− mice are hypersensitive to insulin, lean and resistant to high-fat-diet-induced obesity [11] [12] [13] . PTP1B also has been implicated as a negative regulator of several other receptortyrosine kinases (RTKs), and is suggested to regulate pyruvate kinase M2 and PERK [14] [15] [16] . Surprisingly, however, PTPN1 is amplified (∼5%) and overexpressed (∼72%) in many breast tumours 17, 18 , and several years ago, we and others reported that mouse Ptpn1 is required for efficient mammary tumorigenesis by Her2/Neu 19, 20 . Furthermore, mammary-specific overexpression of PTP1B causes breast tumours 20 . The underlying mechanism of the pro-oncogenic effects of PTP1B has remained unclear/controversial 19, 20 , however, as has its role in human HER2 + breast cancer.
Moyamoya disease is a rare disorder (incidence ∼1:100,000) 21 that occurs in sporadic and inherited forms. Characterized by vascular occlusions, usually affecting the circle of Willis, it typically presents in adolescents or young adults. The inherited form is strongly associated with single nucleotide polymorphisms in RNF213, which encodes a large protein (relative molecular mass 591,000 (M r 591K)) containing AAA+ ATPase and E3-ligase domains. Up to 1% of the Japanese population, and other Asians, have the causative single nucleotide polymorphism, suggesting that important environmental contributors and/or genetic modifiers must exist.
In studying the effects of PTP1B deficiency on HER2 + breast cancer (BC) lines, we found that PTP1B is essential for their response to severe hypoxia in vitro and in vivo. Further analysis uncovered a previously unreported pathway involving PTP1B, RNF213 and α-KGDDs. Hence, our results reveal unexpected connections between tyrosine phosphorylation, moyamoya disease, α-KGDDs and the regulation of NMOC in the tumour microenvironment.
RESULTS
PTP1B is required for tumorigenicity of HER2 + BC cells To explore its potential role in human HER2 + BC, we depleted PTP1B from several HER2 + BC lines by stably expressing PTPN1 short hairpin RNA (shRNA; Supplementary Fig. 1a ). PTP1B deficiency did not affect cell proliferation in normal media (10% serum), low serum (1% serum), low density, low glucose (0.5 g l −1 ) or in the absence of glutamine ( Supplementary Fig. 1b,c ). PTP1B deficiency also had no consistent effect on growth factor signalling, as assessed by pSTAT3, pAKT and pERK levels ( Supplementary Fig. 1d ). Nor did PTP1B deficiency attenuate colony formation in soft agar or Matrigel; in fact, for some lines, lack of PTP1B resulted in increased colony size ( Supplementary Fig. 1e,f) . Hence, we conclude that PTP1B is not required for proliferation of HER2 + BC cells in vitro.
Ptpn1-deficiency delays the onset of breast tumours and prolongs the survival of MMTV-Neu NT mice (refs 19,20 ; also see Supplementary Fig. 2a ), so we investigated the role of PTP1B in tumour initiation by human HER2 + BC cell lines. In marked contrast to its lack of effects in vitro, but consistent with the effects of an allosteric PTP1B inhibitor 22 , PTPN1-KD inhibited HER2 + tumour growth ( Fig. 1a ). Re-expressing wild-type (WT) mouse PTP1B (m1B) in 1B-KD cells by using a Ptpn1 complementary DNA (which is PTPN1 shRNA-resistant) rescued tumour growth. By contrast, the catalytically impaired R221M mutant (m1B-RM) could not restore tumorigenicity (Fig. 1b) . Therefore, the anti-tumorigenic effects of the PTPN1 shRNA are 'on-target' , and PTP1B catalytic activity is required for its pro-tumorigenic effects. PTP1B expression also was required for tumour maintenance, as shown by experiments using an IPTG-inducible PTPN1 shRNA (i1B-KD) expressed in BT474 cells (Fig. 1c ). Despite the marked effect of PTP1B deficiency on tumour growth, there were no consistent differences in MEK, ERK, AKT or S6 phosphorylation in parental versus PTP1B-deficient tumours ( Supplementary Fig. 3a ). Consistent with a mouse model 23 , immunohistochemical analysis showed no consistent difference in proliferation (BrdU incorporation/Ki67) or angiogenesis (CD31) as a consequence of PTP1B deficiency ( Supplementary Fig. 3b-d ).
PTP1B deficiency/inhibition sensitizes HER2 + BC cells to hypoxic cell death PTP1B-deficient HER2 + tumours, although substantially smaller, were more necrotic ( Fig. 1d ; red arrows) and more hypoxic, as shown by EF5 immunostaining (Fig. 1d,e and Supplementary Fig. 3e ). Inducing PTPN1-shRNA expression after tumours had started to form resulted in markedly increased EF5 reactivity (Fig. 1f,g and Supplementary Fig. 3f ), indicating that increased hypoxia was an acute effect of PTP1B depletion, rather than a response to sustained PTP1B deficiency. Similar effects were observed in a mouse model: although nine-month-old Ptpn1 −/− ; MMTV-Neu NT and Ptpn1 +/+ ; MMTV-Neu NT mice had comparable numbers of hyperplastic lesions, in PTP1B-deficient animals, these lesions displayed more EF5 staining ( Supplementary Fig. 2b-d ). Hence, we conclude that PTP1B controls HER2 + tumour hypoxia and survival.
Next, we assessed the effect of PTP1B deficiency on HER2 + BC cells exposed to hypoxia in vitro. PTPN1-KD decreased the survival of multiple HER2 + lines in bulk culture ( Fig. 2a ) and in clonogenic assays ( Fig. 2b ) following exposure to 0.1% or 0.2% O 2 , respectively. Importantly, expressing WT m1B, but not m1B-RM, rescued hypoxiainduced cell death in 1B-KD cells (Fig. 2c ). Conversely, treatment with a specific PTP1B inhibitor 24 induced cell death in parental HER2 + BC cells exposed to hypoxia, but had no effect in normoxia, indicating that the protective effect of PTP1B in hypoxia is phosphatase activity dependent ( Fig. 2d ). As in tumours, PTPN1-KD BC cells underwent non-apoptotic death after exposure to 0.1% O 2 ( Supplementary  Fig. 4a,b) .
Surprisingly, the increased death of PTPN1-deficient BC cells in low oxygen was not accompanied by defective activation of the known hypoxia response pathways, including HIF1α, UPR or mTOR, as assessed by HIF1α stabilization and activity, and phosphorylation of eIF2α or S6, respectively ( Supplementary Fig. 4c -g). Instead, HIF1α stabilization and eIF2α phosphorylation actually occurred earlier in some 1B-KD BC cells, suggesting that they might be experiencing more severe hypoxia than parental cells. 1  3  5  7  9 11  1 2 3 4 5 6 7 8  1 2 3 4 5 6 7  1 3 5 7 9 11 13 
Figure 1
Increased hypoxia and necrosis in PTP1B-deficient HER2 + breast tumours. (a) Tumour growth from control and 1B-KD HER2 + breast cancer cells injected subcutaneously into athymic nude mice. Independent mice were injected at the beginning of the experiment (n = 10 biologically independent xenografts for all groups except MDA-MB-361 1B-KD, where n = 8). Tumours were collected during the experiment for histology and immunohistochemistry, leaving n = 5 for the BT474 group at week 9-11, n = 8 for the HCC1954 group at week 5-7, and n = 9 for the MDA-MB-361 mice and n = 7 for the MDA-MB-361 1B-KD mice at week 11-13. (b) Tumour growth from mice injected with BT474 (n = 10), BT474 1B-KD (n = 7), BT474 1B-KD + mPtpn1 WT (n = 9) or BT74 1B-KD + mPtpn1 RM (n = 10) cells. All n values represent biologically independent xenografts. (c) BT474 cells expressing IPTG-inducible PTPN1 shRNA (i1B-KD) were allowed to form small tumours. IPTG was added to drinking water of half of the mice (n = 5 biologically independent xenografts). Immunoblots in a-c show PTP1B levels in individual tumours at the endpoint of each experiment; ERK2 or eIF2α are loading controls. Note the nonspecific band ( * ) on the mPTP1B immunoblot in b. (d) Representative sections from BT474 xenografts (from b) at 11 weeks post-injection, stained with H&E or EF5 (hypoxia). Insets and main images represent ×0.4 or ×10 magnifications, respectively. Red arrows indicate necrosis. (e) EF5 staining area, normalized to tumour size, from BT474 (n = 9), BT474 1B-KD (n = 6), BT474 1B-KD + mPtpn1 WT (n = 9), JIMT1 (n = 6), JIMT1 1B-KD (n = 6), HCC1954 (n = 5) and HCC1954 1B-KD (n = 5) xenografts (from a and b Table 8 ). Graphs represent mean ± s.e.m. and were compared by two-way (a-c) or one-way (d) ANOVA, followed by Bonferroni post hoc test.
uncoupling agent) or rotenone (mt complex I inhibitor) plus antimycin A (mt complex III inhibitor). Consistent with the observed HIF1α activation (see above), mitochondrial OCR was reduced in hypoxiaexposed parental and PTP1B-deficient cells, compared with their normoxic counterparts. In hypoxia-exposed conditions, however, the OCR was higher in HER2 + (BT474) 1B-KD cells than in parental cells. This difference was also evident in normoxic conditions in the presence of oligomycin or when rotenone and antimycin A were added to block the electron transport chain (Fig. 3a) . These results indicated that NMOC was increased in BT474 1B-KD cells. Consistent with this notion, there was no increase in mitochondrial mass or activity in such cells ( Supplementary Fig. 5a -c). The effects of PTP1B deficiency on cell survival were restricted to severe hypoxia (0.1%-0.5% O 2 ); survival of parental and 1B-KD cells was similar at higher oxygen concentrations ( Fig. 3b ). Moreover, 1B-KD and parental cells died at similar rates under anoxia. These findings suggest that in severe hypoxia, PTP1B-deficient HER2 + BC cells fail to inhibit NMOC and thus deplete remaining oxygen reservoirs faster than parental cells. In parallel, we analysed metabolites in two HER2 + BC (BT474 and SKBR3) cell lines using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Principal component analysis revealed global alteration of the metabolome in the PTP1B-deficient cells, which was restored by mPTP1B expression ( Supplementary Fig. 6a -e and Supplementary Table 1 ). Control and PTP1B-deficient BT474 and SKBR3 cells showed multiple PTP1B-dependent alterations in metabolite levels, but the only shared difference was an ∼2-fold lower Figure 3 PTP1B-deficient BC cells die due to increased NMOC. (a) Oxygen consumption rate (OCR) in control and 1B-KD BT474 cells after exposure to normoxia (21% O 2 ) or hypoxia (0.1% O 2 ) for 24 h. Oligomycin inhibits coupled respiration; FCCP was added to measure maximal respiration; rotenone and antimycin A block electron transport, enabling measurement of NMOC (n = 4 biologically independent experiments for each group and condition; also see Supplementary Table 8 ). (b) Effect of oxygen concentration on PTP1B-deficient HER2 + BC cells. Survival of control and 1B-KD BT474 and HCC1954 cells in anoxia (0%) or at the indicated O 2 concentrations (n = 3 biologically independent experiments for each group and condition; also see Supplementary  Table 8 ). Graphs represent mean ± s.e.m., and were compared using one-way (a) or two-way ANOVA (b), followed by Bonferroni post hoc test.
level of α-KG in PTP1B-deficient cells ( Fig. 4a,b ). This decrease could not be explained by consistent differences in the levels of glutamine metabolism enzymes or by altered isocitrate dehydrogenase activity ( Supplementary Figs 5d and 6f ).
Increased NMOC, concomitant with decreased α-KG levels, could enhance increased activity of one or more α-KG-dependent dioxygenases (α-KGDDs) [6] [7] [8] [9] . Consistent with this notion, there was an increase in the number and intensity of bands detected with anti-hydroxyproline antibodies in 1B-KD HER2 + BC cells, which was reversed on treatment with the generic α-KGDD inhibitor IOXI ( Fig. 4c-h) . Several α-KGDDs catalyse prolyl hydroxylation, so these differences could reflect increased activity of multiple (if not all) family members, not just HIF1α hydroxylases. Carnitine biosynthesis requires another α-KGDD, γ-butyrobetaine dioxygenase (BBOX). Remarkably, carnitine levels were increased in PTP1Bdeficient HER2 + BC cells in normoxia or hypoxia ( Fig. 4i) , consistent with increased BBOX activity. DNA from PTP1B-deficient HER2 + BC cells in normoxia or hypoxia also showed globally decreased reactivity to an antibody against 5-methyl cytosine, whereas reactivity was restored on IOXI treatment ( Fig. 4j,k ). This finding could reflect increased activity of TET family DNA demethylases, which also are α-KGDDs. Together, these results suggest that multiple α-KGDD-dependent pathways are activated in PTP1B-deficient HER2 + BC cells.
Most importantly, pre-treatment with the generic α-KGDD inhibitors IOXI or DMOG [26] [27] [28] protected 1B-KD HER2 + BC cells from hypoxia-induced death in a dose-dependent manner (Fig. 5a,b ), and normalized the increased NMOC in PTP1B-deficient cells ( Fig. 3e ). As expected, IOXI addition decreased maximal OCR, consistent with HIF1α stabilization as a consequence of HIF prolyl hydroxylase inhibition. Together, these findings suggest that PTP1B controls the activity of one or more α-KGDDs to regulate NMOC and, potentially, α-KG levels.
RNF213 is a putative PTP1B substrate
Our results show that PTP1B catalytic activity is required to prevent hypoxia hypersensitivity. To search for PTP1B substrates that might mediate hypoxia hypersensitivity in the absence of PTP1B, we stably expressed Flag-mPtpn1 WT or an mPtpn1 'substrate-trapping' mutant (CS/DA) in BT474 1B-KD cells. mPTP1B CS/DA is a double mutant of the catalytic cysteinyl residue (C215S) and the aspartyl residue (D181A) that acts as a general acid to effect PTP catalysis; such mutants can bind, but not promote hydrolysis of, substrates 29 . As reported previously 30 , Flag-mPTP1B CS/DA 'trapped' the EGFR from lysates of EGF-stimulated cells ( Supplementary  Fig. 7a ). Unbiased MS identification of potential mPTP1B substrates from normoxic or hypoxic cells did not identify known α-KGDDs or α-KGDD regulators. Instead, two proteins, ARHGAP12 and RNF213, were enriched substantially in Flag-mPTP1B CS/DA co-immunoprecipitations ( Supplementary Fig. 7b ). ARHGAP12 is a RHO-GTPase-activating protein (also known as RHOGAP12) thought to be involved in cell motility 31 , and was suggested to be a PTP1B substrate in an earlier proteomic study 32 . We confirmed the preferential interaction of ARHGAP12 with substrate-trapping 37 P < 0.0001 P < 0.0001 P = 0.0004 P = 0.0004 P = 0.0050 P = 0.0356 SKBR3 0 0.5 mutants; however, ARHGAP12 depletion (with short interfering RNA (siRNA)) had no effect on the hypoxia sensitivity of parental or 1B-KD HER2 + BC cells ( Supplementary Fig. 7c,d) .
RNF213 is an M r 591K protein containing a RING E3 ligase and an AAA+ ATPase domain 33 , but had not previously been implicated in PTP1B action. We validated the interaction of RNF213 with Plots show mean ± s.e.m. from n = 3 biologically independent experiments for each condition (also see Supplementary Table 8 ). (c) OCR of parental and 1B-KD BT474 cells with or without overnight exposure to IOXI (100 µM) or the indicated mitochondrial inhibitors (n = 5 biologically independent experiments for each group and condition). All graphs represent mean ± s.e.m., and were compared by one-way ANOVA (a-c), followed by Bonferroni post hoc test.
PTP1B CS/DA and with another trapping mutant, PTP1B D/A, by immunoblotting ( Fig. 6a ). PTP1B/RNF213 interaction appears to require the PTP1B catalytic centre, because the competitive inhibitor sodium vanadate (Na 3 VO 4 ) preferentially interfered with RNF213 binding to Flag-mPTP1B DA, which retains its active site cysteine, compared with Flag-mPTP1B CS/DA (Fig. 6b ). Consistent with these observations, RNF213 is tyrosine-phosphorylated, although there was no obvious difference in overall phosphotyrosine (pY) levels on RNF213 in parental versus 1B-KD HER2 + BC cells (Fig. 6c ). The latter result suggests that PTP1B targets specific sites on RNF213. Most importantly, RNF213 knockdown rescued multiple 1B-KD HER2 + BC cells from hypoxia-induced cell death ( Fig. 6d ). Furthermore, whereas RNF213-KD alone had minimal effects on OCR, it corrected the increased NMOC in BT474 1B-KD cells to levels comparable to parental cells ( Fig. 6e ), normalized the increase in IOXI-dependent, hydroxyproline antibody-reactive bands ( Fig. 6f ) and restored DNA methylation to parental levels (Fig. 4k ). In addition, RNF213-KD decreased HIF1α hydroxylation in 1B-KD, but not parental, HER2 + BC cells, providing evidence that PTP1B/RNF213 can regulate specific hydroxylation events ( Supplementary Fig. 7e,f) . Finally, RNF213-KD partially (but significantly) restored the growth of 1B-KD HCC1954 tumours (Fig. 6g-i and Supplementary Fig. 7g -i), while normalizing their increased staining with EF5.
PTP1B regulates RNF213 E3 activity and globally affects ubiquitylation in HER2 + BC cells
The above findings indicated that PTP1B negatively regulates RNF213. To examine the biochemical effects of PTP1B on RNF213 and to identify potential RNF213 substrates, we expressed HA-tagged ubiquitin (HA-Ub) in control and 1B-KD HER2 + cells. Remarkably, PTP1B deficiency or inhibition substantially increased overall ubiquitylation (by immunoblotting), and much of this increase was suppressed by RNF213-KD ( Fig. 7a-d and Supplementary Fig. 7j,k) . We also generated RNF213 knockout (RNF213-KO) BT474 cells by using the CRISPR/Cas9 system. Consistent with the effects seen in RNF213-KD cells, PTP1B inhibitor treatment resulted in increased Supplementary Table 8 ). Supplementary  Fig. 8 . ubiquitylation in BT474 cells, but not in the RNF213-KO cells (Fig. 7e ). RNF213-KD or -KO alone also decreased overall ubiquitylation in parental BT474 cells. As noted above, IOXI protected PTP1B-deficient HER2 + BC cells from hypoxia-induced death, but it did not normalize the increased level of ubiquitylated proteins in these cells (Supplementary Fig. 7l ). Hence, α-KGDD regulation is downstream of RNF213.
We used two distinct, but complementary, methods, HA-Ub immunoprecipitation-mass spectrometry (IP-MS) and DiGly IP-MS, to identify and quantify changes in the ubiquitylome ( Supplementary Fig. 7m and Supplementary Tables 2 and 3) 34 . Consistent with the results of our immunoblotting experiments, nearly 40% of the ubiquitylome was increased in 1B-KD BT474 cells, and most (>60%) of this increase was suppressed by RNF213-KD (Fig. 7f ). Pathway analysis of PTP1B/RNF213-dependent ubiquitylated proteins revealed marked enrichment for proteins involved in ubiquitin-mediated proteolysis (E1s, E2s, E3s and deubiquitylases; Supplementary Table 4 ).
These results suggested that PTP1B negatively regulates RNF213 E3-ligase activity. Indeed, RNF213 auto-ubiquitylation activity was enhanced in 1B-KD BT474 cells, compared with their parental counterparts (Fig. 7g ). Regulation of multiple proteins involved in ubiquitin-mediated proteolysis by RNF213 could explain the large changes in ubiquitylation in PTP1B-deficient HER2 + BC cells.
DISCUSSION
We have discovered that PTP1B is required for the survival of HER2 + BC cells in severe hypoxia. Genetic and biochemical evidence suggest that RNF213 is a PTP1B substrate, which in turn controls the activity of one or more IOXI/DMOG-sensitive α-KGDDs (Fig. 7h ). We propose that, in normoxic conditions, the excess NMOC caused by these enzymes in PTP1B-deficient cells can be tolerated. By contrast, in the hypoxic tumour microenvironment, excessive NMOC (caused by increased α-KGDD activity) results in oxygen depletion and necrotic cell death (Fig. 7h) . Therefore, in parallel to the well-described regulation of mitochondrial oxygen consumption by HIF, control of NMOC by this PTP1B/RNF213/α-KGDD pathway appears to be essential for hypoxic survival of tumour cells. Our results also identify RNF213 as a major regulator of the ubiquitylome, at least in HER2 + BC cells.
Ptpn1 deficiency impairs the ability of oncogenic alleles of Neu (rat HER2) to cause BC in mice 19, 20 . However, whereas ref. 20 reported decreased ERK and AKT activation in tumours that eventually arose in the PTP1B-deficient animals, we saw no consistent effect on ERK or AKT in the rare tumours that arose in compound mutant mice 19 . We did observe a consistent decrease in ERK activity in PTP1Bdeficient hyperplastic lesions, but these changes were small and of uncertain biological consequence. Similarly, we observed no effect of PTP1B deficiency or inhibition on cell proliferation, viability or HER2 signalling events in human BC lines in vitro or in the tumours. Recently, ref. 22 reported that MSI-1436, an allosteric inhibitor of PTP1B, impaired HER2 cell proliferation in vitro. Notably, those experiments used surrogate assays for proliferation rather than the direct cell counts used here.
Several lines of evidence indicate that RNF213 is a substrate of PTP1B, and that PTP1B negatively regulates RNF213. First, RNF213 preferentially binds to two substrate-trapping mutants of PTP1B. Interaction with the substrate-trapping mutant containing an intact catalytic cysteine (DA) is preferentially disrupted by the competitive inhibitor sodium orthovanadate, compared with the trapping mutant (CS/DA) without a catalytic cysteine. These results suggest direct interaction between RNF213 and the PTP1B catalytic centre. Furthermore, RNF213 from PTP1B-deficient cells shows increased in vitro auto-ubiquitylation activity. Nevertheless, tyrosine phosphorylation of RNF213 is not increased in PTP1Bdeficient/inhibited cells. We suspect that only a specific tyrosine(s) is regulated by PTP1B; nevertheless, RNF213 should be viewed as a putative substrate until such residues are identified. Regardless, our RNF213-KD and -KO experiments show clearly that RNF213 is the essential downstream mediator of the effects of PTP1B on hypoxia sensitivity. Conceivably, the vascular occlusions, increased VEGF production, and abnormal blood vessel generation 33, 35, 36 in moyamoya disease also reflect a de-regulated hypoxia response.
Our results also link RNF213 to the control of α-KGDDs. Although the precise mechanism is unclear, we suspect that one or more RNF213 substrates globally regulate α-KGDDs by altering the levels of co-substrates/metabolites, such as ascorbate and/or iron. It also is tempting to speculate that sub-clinical deficiency of these substances could represent a contributing environmental factor(s) in moyamoya disease pathogenesis.
Although we focused on the role of PTP1B in HER2 + BC, PTPN1 is amplified in other malignancies, including colorectal (10.1%) and ovarian (8%) cancers 37 . Future work will focus on whether PTP1B has a broader role in controlling hypoxic survival in tumours and on defining the function, substrates and regulators of RNF213. Such studies could suggest new therapeutic approaches for HER2 + BC and other malignancies. Although small-molecule inhibitors of PTP1B have been sought primarily for the treatment of diabetes and obesity, our results suggest that PTP1B inhibition, perhaps in combination with agents that preferentially kill normoxic cells (for example, radiation) or drive tumours towards a hypoxic state (for example, anti-angiogenics), could be beneficial in cancer therapy. Finally, it will be important to clarify the potential role of PTP1B, α-KGDDs and NMOC in moyamoya disease pathogenesis.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper. 38 was purchased from EMD Millipore. IOXI (CAS 5852-78-8) was purchased from Cayman Chemicals. Oligomycin A, FCCP (trifluorocarbonylcyanide phenylhydrazone), rotenone and DMOG (dimethyloxaloglycine) were purchased from Tocris Bioscience. Antimycin A was purchased from Enzo Life Sciences.
Note: Supplementary Information is available in the online version of the paper
Rabbit polyclonal anti-RNF213 antibodies were generated and used as described previously 39 . Other antibodies were purchased and used for immunoprecipitations and/or immunoblotting at manufacturer-recommended concentrations ( Supplementary Table 5 ).
Cell culture, infections and transfections. Breast cancer lines were purchased from the American Type Culture Collection or Deutsche Sammlung von Mikroorganismen und Zellkulturen. No lines used in this study are found in the ICLAC or NCBI Biosample databases of commonly misidentified cell lines. All cell lines were authenticated by STR profiling (GenePrint 10 System -10 marks, Centre for Applied Genomics, Hospital for Sick Children, Toronto), and tested for mycoplasma (MycoAlert, Lonza). BT474, SKBR3, MDA-MB-361 and JIMT1 cells were maintained in DMEM+10% FBS. HCC1954 cells were cultured in RMPI+10% FBS. Where indicated, cells were stably infected with VSVGpseudotyped retroviruses carrying pSuper-puro control shRNA or PTPN1 shRNA or VSVG-pseudotyped lentivirus harbouring pLKO (901)-IPTG-inducible-puro PTPN1 shRNA. Reconstitution of PTP1B was achieved by infecting cells with the VSVG-pseudotyped retrovirus pFB-neo mPtp1b-wild-type, the catalytically impaired mPtp1b mutant (R221M), Flag-mPtp1b-wild-type or a Flag-substratetrapping mutant (D181A or D181A/C215S). To obtain stable transductants, infected cells were treated with 1.5 µg ml −1 (BT474/SKBR3), 3 µg ml −1 (MDA-MB-361), 4 µg ml −1 (HCC1954), or 7 µg ml −1 (JIMT1) puromycin (Bioshop) for 3 days or with 700 µg ml −1 G418 (Bioshop) for 7 days. Smartpools or individual siRNAs for RNF213, ARHGAP12 and IDH1 (Thermo Scientific) were introduced into cells using Lipofectamine RNAiMAX (Invitrogen), as per the manufacturer's instructions. All RNAi and shRNA sequences are shown in Supplementary Table 6 .
For soft-agar assays, 5,000 cells were mixed into 0.3% agar (top layer), and seeded onto 10 cm plates containing a 0.6% agar (bottom) layer. Media were changed every 4 days for 4 weeks. Images were obtained at 4× magnification using a Leica DFC420 digital camera and Leica FireCam software. Colonies were counted in 10 fields using a 0.25 cm 2 grid.
For Matrigel assays, 48-well plates were coated with 3-D Culture Matrix-Reduced Growth Factor Basement Membrane Extract (Cultrex), and incubated at 37 • C for 30 min. Each well was seeded with 5,000 cells in 500 µl of growth media. Media were changed every 4 days for 3 weeks, and images were obtained as above.
Xenografts, mouse models and histology. Breast cancer cells (1 × 10 6 ) were suspended in 40 µl of 50% growth factor-reduced Matrigel (BD Science), and injected subcutaneously into the right flanks of 6-8-week-old female Balb/c athymic nude mice implanted with (BT474 and MDA-MB-361) or without (JIMT1 and HCC1954) a 60-day release pellet containing 0.72 mg 17β-oestradiol (Innovative Research of America). Experiments were not randomized, nor were the investigators blinded to allocation during experiments and outcome assessment. Tumours were measured weekly with callipers, and tumour volume was calculated as length × width 2 × 0.52 (ref. 40) . For tumour maintenance experiments, IPTG (1 mM) was added to the drinking water to induce expression of PTPN1 shRNA. No statistical method was used to pre-determine sample size, but based on the results of a pilot experiment consisting of 9 mice each for parental and 1B-KD BT474 tumours, power analysis indicated that 8 mice per group were sufficient to detect an approximately threefold difference in mean tumour size. Ptpn1 −/− and MMTV-Neu NT mice (mixed background, 129/B6/FVB) were described previously 41 . Females containing one copy of MMTV-Neu NT from Ptpn1 +/− × MMTV-Neu NT ; Ptpn1 +/− crosses were kept as virgins for the entire study period. Mice that died for unknown reasons were excluded from analysis. All animal studies were approved by the University Health Network Animal Care Committee (Protocol no. 1239).
Before euthanizing, mice were injected with 1.5 mg BrdU and 2 µmol EF5 for 24 h or 4 h, respectively. Tumours and mammary glands were fixed in formalin and embedded in paraffin. Sectioning and H&E staining were performed by the University Health Network Pathology Research Program (UHN PRP). Immunohistochemical analyses were performed by the UHN PRP or the Princess Margaret Cancer Centre Applied Molecular Profiling Laboratory (AMPL). Slides were scanned at the Princess Margaret Cancer Center Advanced Optical Microscopy Facility, and analysed with Aperio ImageScope software (Leica Biosystems). In each sample, the percentage of EF5 staining was normalized to tumour size.
In vitro hypoxia assays. Cells were seeded at 2 × 10 6 cells per 60 mm plate (4 × 10 6 per plate for MDA-MB-361), and allowed to adhere overnight. The next day (Day 0), cells were counted, and the medium (3 ml) was exchanged, before replicates were placed into a standard incubator (normoxia), tri-gas incubator (5% O 2 , Sanyo MCO-18M), hypoxia chamber (0.1-1.0% O 2 , Whitley H35 Hypoxystation) or anoxic chamber (0% O 2 , Whitley H85 Hypoxystation). PTP1B inhibitor and/or the oxygenase inhibitors IOXI or DMOG were added after the medium was changed on Day 0, but before placing cells in the normoxia or hypoxia chamber. Cells remaining on the plate were counted at the indicated times. Experiments were scaled up or down onto different sized plates on the basis of surface area. For colony formation assays, cells were exposed to normoxia or 0.2% O 2 hypoxia for 24 h, and then reseeded onto 10 cm plates at the indicated densities in triplicate. Media were changed every 3 days for 3-4 weeks. Colonies were stained using methylene blue and counted.
Generation of RNF213-knockout BT474 cells. An RNF213-knockout BT474 cell line was generated by CRISPR/Cas9-mediated genome engineering 42 . Briefly, a target sequence in the third exon of RNF213 (ACAATGGCGTCGGCCTCGGA) was designed by consulting the website http://crispr.mit.edu, and cloned into the BbsI site of pSpCas9 (BB)-2A-GFP (PX458) (Addgene). BT474 cells were transfected with the PX458-sgRNF213 vector using FuGENE 6 Transfection Reagent (Promega). Forty-eight hours post-transfection, GFP-positive cells were sorted, cultured at limiting dilution and single clones were isolated. Homozygous RNF213 mutation was identified by DNA sequencing and confirmed by immunoblotting.
Flow cytometry. Cell death was analysed by Sytox Blue and Annexin V staining. Culture supernatants and trypsinized cells were collected, combined and recovered by centrifugation at 365g in a tabletop centrifuge (Beckman Coulter). Cells were washed with Hanks' Balanced Salt Solution (HBSS, Wisent), resuspended in 1× Annexin V binding buffer (BD Science) and stained with Annexin V-PI (BD Pharmingen) and Sytox blue (Invitrogen), as recommended by the manufacturers. Total and active mitochondria were stained with Mitotracker dyes (Invitrogen). Cells were stained with 200 µM of Mitotracker Green and CMXROS (both from Invitrogen) for 30 min. All samples were analysed using a Becton Dickinson (BD) LSRII (BD Biosciences) and FlowJo software.
Quantitative real-time PCR. Cellular RNA was extracted by using the miRNeasy kit (Qiagen), and then reverse transcribed using the RT 2 first stand kit (Qiagen). The resultant cDNA (20 ng) was mixed with SYBR Green Supermix (Qiagen and Life Technologies), along with primers specific to HIF1α target genes, as described previously 43 , or analysed by using the RT 2 profiler PCR array-human hypoxia signalling pathway (see Supplementary Table 7 ). Reactions were performed on the CFX96 real-time PCR machine (Bio-Rad). CT was calculated using RPL13A as a loading control. Fold change was calculated relative to parental HER2 + breast cancer cells in normoxia.
Oxygen consumption measurements.
Oxygen consumption rate (OCR) was measured with an XF96 analyser (Seahorse Bioscience). Briefly, cells (25,000 per well) were seeded in DMEM (no buffer) + 2%FBS in 96-well plates. The plates were centrifuged at 21g in a tabletop centrifuge (Beckman Coulter) with no deceleration for 5 min, before placement into the analyser. Injection ports were loaded to achieve the following final working concentrations: oligomycin A (1.5 µM), FCCP (1 µM), rotenone (1 µM) and antimycin A (1 µM). Before OCR measurements, cells were exposed to normoxia or 0.1% O 2 hypoxia for 24 h, treated with IOXI overnight (16 h), or transfected with siRNAs for 72 h, as indicated.
Metabolomics. Metabolites were prepared as described previously 44 . Briefly, cells were flash frozen in liquid N 2 , and extracted with 40% acetonitrile:40% methanol:20% H 2 O. Extracts were placed into 1.5 ml Eppendorf tubes (Corning), vortexed at 4 • C for 1 h and centrifuged at 4 • C for 10 min at ∼18,000g in an Eppendorf microfuge. Supernatants were evaporated in a Speedvac (Acid-Resistant CentriVap Vacuum Concentrators, Labconco), and samples were resolved by LC-MS/MS. Analysis was performed in positive and negative modes at the optimum polarity in MRM mode on an electrospray ionization (ESI) triplequadrupole mass spectrometer (ABSciex4000Qtrap), as described previously [44] [45] [46] . Some metabolites appear in duplicate due to using different ions to confirm the metabolites. Principal component analysis and heat maps were generated by using Mass Profiler Professional (Agilent).
DNA methylation dot blots. Genomic DNA and methylated DNA standards (Cat. no. 55008; Active Motif) were heat-denatured in 0.4 M NaOH (Sigma) and 10 mM EDTA (Sigma) at 100 • C for 10 min and chilled on ice for 5 min. Samples were twofold serially diluted and applied to a positively charged nylon membrane (Biodyne B; Pall Life Sciences) using the Bio-dot microfiltration apparatus (Bio-Rad). Membranes were ultraviolet-crosslinked at 120,000 µJ cm −2 (CL1000; UVP), and blocked in TBS, 0.1% Tween-20 (TBST), 5% milk for 1 h. Primary antibodies against 5-mC (1:1,000; cat. 39649; Active Motif) were incubated with the membrane in TBST overnight. Dot blots were washed 3× in TBST, incubated in HRP-conjugated IgG secondary antibodies (GE Healthcare) for 1 h, and detected by standard ECL methods (Supersignal West Pico; Thermo Fisher Scientific).
Immunoblotting and immunoprecipitation. For immunoblotting, whole cell lysates were generated in modified radioimmunoprecipitation (RIPA) buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, 1% NP-40, and 0.1% SDS, without sodium deoxycholate). TNE lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM EDTA, and 1% NP-40) was used for immunoprecipitations. Lysis buffers were supplemented with protease (40 µg ml −1 phenylmethyl sulfonyl fluoride, 2 µg ml −1 antipain, 2 µg ml −1 pepstatin A, 20 µg ml −1 leupeptin, and 20 µg ml −1 aprotinin) and phosphatase (10 mM NaF, 1 mM Na 3 VO 4 , 10 mM β-glycerophosphate, and 10 mM sodium pyrophosphate) inhibitors. Lysates were incubated, as indicated, with anti-RNF213 antibodies and G-Sepharose 4 Fast Flow (GE Healthcare) or anti-Flag M2 agarose (Sigma-Aldrich) for 3 h at 4 • C on a rotating platform. Beads were washed 4× in their respective lysis buffer, and then analysed by immunoblotting, essentially as described previously 47 . To detect RNF213, lysates and immunoprecipitates were resolved by modified SDS-PAGE, using 3-8% Tris-acetate gels and Tris-acetate running buffer (Invitrogen). Tris-acetate gels were transferred in 1× transfer buffer, 10% methanol and 0.1% SDS. All other proteins were resolved by standard SDS-PAGE, and transferred using 1× transfer buffer and 15% methanol 47 . Membranes were incubated with their respective primary antibodies, and visualized with IRDye infrared secondary antibodies, using an Odyssey Infrared imaging system (Li-Cor Biosciences).
Isocitrate dehydrogenase (IDH) activity measurements. IDH activity was measured as described previously 48, 49 . Briefly, cells were lysed in PBS + 0.1% Triton-X-100, supplemented with protease inhibitors as above. Aliquots of each lysate (4 µg protein) were added to assay buffer (25 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 1. Ubiquitylome analysis. Cells were transfected with empty pBabe-puro vector or pBabe-puro expressing HA-tagged ubiquitin (HA-Ub) using Fugene 6 (Promega), as per the manufacturer's instructions. Transfected cells were exposed to normoxia or 0.1% O 2 for 24 h, and treated with and without 10 µM MG132 and 50 µM chloroquine to inhibit the proteasome and lysosome, respectively. Cells were lysed in RIPA buffer (+10 mM IAM and NEM), and lysates were analysed by immunoblotting as described above.
For HA-Ub IP-MS, cells were lysed in RIPA buffer, and lysates were immunoprecipitated with 100 µl of a 50% slurry of HA-agarose beads (Sigma-Aldrich) overnight at 4 • C on a rotating platform. Beads were washed 3× in RIPA buffer, 4× in rinse solution and then eluted with three aliquots (250 µl each) of 0.1% trifluoroacetic acid (TFA). Samples were prepared and cleaned as described in the Protein mass spectrometry section. Lyophilized peptide pellets were resuspended in 10 µl of 0.1% formic acid. LC-MS/MS was performed as described previously 50 , except the entire 10 µl of sample was injected for each analysis.
MaxQuant version 1.5.1.0 was used to search raw data from the mass spectrometer against using the UniProt complete human proteome sequence database (version: 2012-07-19, number of sequences: 20,232) 51 . Carbamidomethylation of cysteines was defined as a fixed modification, and oxidation of methionine and acetylation of protein amino termini as variable modifications. False discovery of peptides was controlled using a target-decoy approach, where peptides under the threshold of 1% false discovery rate were carried on for analysis. Subsequently, protein groups identified with at least two or more peptides were carried forward in analysis. All post-search and statistical analysis of proteomics data was performed using R. LFQ intensities assigned to protein groups were used as a proxy for protein intensities; however, missing LFQ intensities were substituted by adjusted iBAQ intensities. Remaining missing data were imputed with a constant value. Further details are available from A.S. or T.K.
For diGly enrichment, proteins were extracted from cells by adding lysis buffer (8M urea, 150 mM NaCl, 50 mM HEPES (pH 7.5), 1 mM EDTA, protease inhibitor (Roche)), and passing the cells 20 times through a 21G needle. Proteins were reduced with 10 mM TCEP, alkylated with 15 mM NEM, and capped with 10 mM dithiothreitol. Before digestion, proteins were precipitated with chloroform/methanol, and the pellet was resuspended in 8 M urea, 50 mM HEPES using a syringe, as described above. Proteins were diluted in 50 mM HEPES to 4 M urea, and digested with LysC (1:100 enzyme/substrate ratio) for 6 h at 30 • C. This solution was diluted to 1 M urea with 50 mM HEPES before the addition of LysC and trypsin (1:100 enzyme/substrate) and incubation at 37 • C overnight. Before enrichment, peptides were acidified before desalting by passage over C-18 solid phase extraction (SPE) columns (Waters).
Lyophilized peptides from 11 mg of protein were dissolved in 1.5 ml of IAP buffer (50 mM MOPS (pH 7.5), 10 mM Na 2 HPO 4 , 50 mM NaCl), and centrifuged at maximal speed for 5 min to remove insoluble material. Supernatants were removed, and incubated for 2 h at 4 • C with anti-diGly antibody (Cell Signaling Technologies; 32 µg/IP), crosslinked to protein A agarose as described previously 52 . Following binding, supernatants containing unbound peptides were retained, and the beads were washed 2× with IAP and 3× with PBS before elution of enriched peptides with 0.15% TFA. A second enrichment was performed using the unbound peptides from the first enrichment. Eluted peptides were desalted by using a C-18 stage tip.
Isobaric labelling of peptide eluates was performed using 10-plex tandem mass tag (TMT) reagents (Thermo Fisher Scientific) 53 . Before use, TMT reagents (0.8 mg) were dissolved in 40 µl of anhydrous acetonitrile (ACN). Dry, enriched peptides were dissolved in 18 µl of 200 mM HEPES (pH 8.0) and 4 µl anhydrous ACN. Labelling was performed by the addition of 3 µl TMT, followed by incubation at room temperature for 1 h. Reactions were quenched with 2 µl of 5% hydroxylamine (3% v/v hydroxylamine). Samples were mixed and desalted by Stage Tip before analysis by mass spectrometry.
Spectra were acquired on an Orbitrap Fusion mass spectrometer, coupled to an Easy-nLC 1000 (Thermo Fisher Scientific) 54 . Peptides were separated over an analytical column (100 µm ID) packed with 0.5 cm of Magic C-18 (5 µm, 100 A, Michrom Bioresources) and 35 cm of Sepax Technologies GP-C18 resin (1.8 µm, 120 A), using a linear gradient from 8 to 26% ACN with 0.125% formic acid over 180 min at a flow rate of 450 nl min −1 . High-resolution (120,000 resolving power, AGC = 200,000) survey scans (MS1) were used to guide data-dependent sampling and subsequent CAD fragmentation (NCE = 35) of the top ten most-intense peptides. MS2 fragment ions were analysed in the ion trap (MS2 AGC = 5,000, MS3 AGC = 50,000), and the top 10 fragment ions were isolated by synchronous precursor selection, fragmented by HCD (NCE = 55) to produce TMT 10-plex reporter ions, and analysed in the Orbitrap at a resolution of 60,000 (refs 55,56) . Precursors with unassigned or +1 charge states were excluded, and previously interrogated precursors were excluded using a dynamic window (60s, ± 10 ppm) around the assigned monoisotopic peak.
A compilation of in-house software was used to convert mass spectrometric data to mzXML format, as well as to correct monoisotopic m/z measurements and erroneous peptide charge state assignments. MS/MS spectra were mapped to peptide sequences by using SEQUEST 57 to search an in silico tryptic digest (2 missed cleavages) of a Uniprot protein database containing target and decoy human proteins, as well as known contaminants. SEQUEST searches allowed a 50 ppm precursor ion tolerance and a 0.9 Da fragment ion tolerance. TMT labels on peptide N termini/lysine residues (+229.16293 Da) and N -ethylmaleimide on cysteine residues (+125.12528 Da) were set as static modifications, whereas methionine oxidation (+15.99492 Da) and the di-glycine ubiquitin remnant modification of lysine residues (+114.04293 Da) were set as dynamic modifications. Peptide spectral matches were filtered to 1% FDR by applying the target-decoy strategy, as described previously 58 . Subsequently, proteins were grouped and filtered to 1% FDR 56 . Following protein grouping, a modified version of Ascore was used to confidently (P ≤ 0.05) localize ubiquitylation sites (Ascore >13) 59 .
Analysis of HA-Ub IP-MS was performed on two independent biological replicates. Increases and decreases from LFQ and pINT (LFQ + iBAQ) were combined and scored if they appeared in either biological replicate. Proteins from the diGly list were scored if at least one peptide was increased in PTPN1-KD cells alone, decreased in RNF213-KD cells alone or increased in PTPN1-KD cells and decreased in RNF213-KD cells, as indicated in the figure and table legends.
Auto-ubiquitylation assays. BT474 parental and 1B-KD cells were transfected with 3xFlag-RNF213 WT by using Fugene 6 (Promega) and following the manufacturer's instructions. Transfected cells were placed in normoxia for 24 h, and lysed with TNE lysis buffer, followed by anti-Flag M2 agarose co-immunoprecipitation, as described above. Auto-ubiquitylation assays were performed in a buffer (30 µl, 1.5× beads volume) containing 50 mM Tris-Cl pH 8.0, E1/UBE1 (250 nM, Boston Biochem), E2/UBE2D2 (10 µM, Boston Biochem), ubiquitin (20 µM, Boston Biochem), ATP (2 mM) and MgCl 2 (10 mM). After incubation at 37 • C for 60 min, reactions were terminated by the addition of SDS-PAGE sample buffer, and resolved using 3-8% DOI: 10.1038/ncb3376
Tris-acetate gradient SDS-PAGE gels, as described above. Ubiquitylated RNF213 species were visualized by immunoblotting, using anti-RNF213 rabbit polyclonal antibodies, as indicated.
Bioinformatic analyses.
Proteins showing ≥1.5-fold increased ubiquitylation in PTPN1-KD cells, ≤0.67-fold decreased ubiquitylation on RNF213-KD or that were affected both by PTPN1-KD and RNF213-KD were compared to find common sets of overlapping proteins 60 Supplementary Table 8 . Each dot blot and immunoblot was performed at least twice if more than one cell line was studied or at least three times if only a single line was used. All xenografts represent one independent experiment with the indicated biological replicates, and each immunoblot contained multiple tumour lysates (biological replicates) from each group. All metabolomics data represent n = 5 technical replicates for each group from a single independent experiment. All immunohistochemical images show samples from a single mouse of each group, and quantification was performed on all biological replicates in the experiment, with the number of data points indicating the number of independent biological replicates. Non-normally (skewed) distributed data (Fig. 2d ) were normalized by log 2transformation. The multilevel t-test was implemented using the R package 'nlme' (https://cran.r-project.org/web/packages/nlme). The between-group variances were similar, and the data were normally distributed. All analyses and graphs were generated with GraphPad Prism 5. A P value of <0.05 was considered significant; precise P values can be found in the figures. . Data points represent mean values from three independent experiments done on different days; see Supplementary Table 8 for raw data. c, Growth curves of the indicated cells maintained in low serum (1% FBS), low glucose (0.5g/L) or no glutamine conditions. Shown are data from three (low serum, low glucose) or two (low glutamine) independent experiments; see Supplementary Table 8 for Supplementary Figure 4 PTP1B-deficient HER2 + BC cells undergo nonapoptotic cell death in hypoxia (0.1% O 2 ), but activate known hypoxia response pathways normally. a, Representative flow cytometric plots of Sytox blue (DNA stain) and Annexin V staining of Control and 1B-KD HER2 + BC cells exposed to 0.1% O 2 for the indicated times. b, Quantification of Annexin V and Sytox Blue populations from a (n=4 biologically independent samples; also see Supplementary Table 8 ). Graphs indicate mean percentage of cells ± s.e.m. Statistical significance was evaluated by two-way ANOVA, followed by Bonferroni post-hoc test. c, No consistent effect on mTOR pathway or autophagy in PTP1B-deficient HER2 + BC cells. Immunoblots show autophagic flux (by LC3 staining) and mTOR-dependent signaling (by pS6 S240/244) in Control and 1B-KD HER2 + BC cells, following exposure to 0.1% O 2 for the indicated times. d, Precocious HIF1a stabilization in PTP1B-deficient HER2 + BC cells. Immunoblots show HIF1a levels and downstream PDH phosphorylation in Control and 1B-KD HER2 + BC cells following exposure to hypoxia (0.1% O 2 ), as indicated; these findings could be explained by the increased oxygen consumption in PTP1B-deficient cells, resulting in early HIF activation. e, Scatter plot showing level of expression of 84 hypoxia genes (assessed by qPCR array) in the indicated Control and 1B-KD HER2 + BC cells exposed to 0.1% O 2 for 8 hrs (SKBR3 and HCC1954) or 24 hrs (BT474 and MDA-MB-361). Array was assessed once for each set of cell lines. f, Expression levels of known HIF1a target genes VEGFA, GLUT1, CA9, PDK1 and REDD1 normalized to RPL13A from Control and 1B-KD HER2 + BC cells exposed to 0.1% O 2 as indicated. For BT474, each gene was measured in three biologically independent replicate experiments. For the other lines, data from a single experiment are shown. For raw values, see Supplementary Table 8 . g, PTP1B-deficient HER2 + cells show precocious activation of UPR. Immunoblot shows PERK activation, as assessed by eIF2a phosphorylation, in Control and 1B-KD BC cells in response to exposure to hypoxia (0.1% O 2 ), as indicated. ERK2 and eIF2a serves as loading controls.
